心脏瓣膜修复材料钙化和抗钙化研究进展  

Progress in calcification and anticalcification research on tissue cardiac valve substitutes

作　　者：宋兵[1] 柳德斌[1] 高百顺[1] 

机构地区：[1]兰州大学第一医院心外科,730000

出　　处：《国际生物医学工程杂志》2010年第5期301-304,316,共5页International Journal of Biomedical Engineering

基　　金：兰州大学中央高校基本科研业务费专项资金资助（860124）

摘　　要：心脏瓣膜生物替代材料发生临床失效的一个主要原因是钙化,其机理非常复杂,涉及一系列决定因素,如含钙细胞外液与膜内磷酸脂反应,形成磷酸钙盐沉积.目前最有效的抗钙化治疗策略有：戊二醛固定组织后加入钙化抑制因子,易钙化位点的剔除或化学修饰,戊二醛固定的改良以及其他化学交联方法.就心脏瓣膜修复材料钙化和抗钙化动物实验研究和临床试验研究进展作一综述.Calcification is a major cause of clinical failure of bioprosthetic and other tissue cardiac valve substitutes.The mechanism of calcification of cardiac valve substitutes is quite complex and has a variety of determinants,involving reaction of calcium-containing extracellular fluid with membrane-associated phosphorus to yield calcium phosphate mineral deposits.The most promising anticalcification strategies have included binding of calcification inhibitors to glutaraldehyde fixed tissue,removal or modification of calcifiable components,modification of glutaraldehyde fixation and use of tissue cross linking agents other than glutaraldehyde.This article reviews current progress toward the research of calcification and anticalcification strategies that are under investigation either in advanced animal models or in clinical trials.

关 键 词：生物材料 心脏瓣膜 钙化 抗钙化 

分 类 号：R318.08[医药卫生—生物医学工程]